H.R. 7640
Referred to CommitteeTo amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").
Introduced 5/3/2022•117th Congress•House
Latest Action
Referred to the House Committee on Energy and Commerce.
5/3/2022 • House
Summary
This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.
Introduced in House • 5/3/2022
Enter your district to see how this bill affects your community
Topics & Subjects
Policy Area: Health
Congressional Votes (0)
No recorded votes yet
Roll call votes will appear here as the bill moves through Congress
Related Federal Spending
Sponsor & Cosponsors (2)
Party Breakdown
1
Democrats
1
Republicans
0
Independents
Sponsor
R[
Cosponsors (1)
R[
Bill Journey
Originated in the House
Introduced
May 3, 2022
Referred to the House Committee on Energy and Commerce.
Committee Review
Floor Debate
Passed Chamber
Other Chamber
President
Enacted into Law
Text Versions (1)
Introduced in House5/3/2022